Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal During Emergence From Sevoflurane-remifentanil Anesthesia

NCT01915108 is registered in ClinicalTrials.gov with Sangjin Park as lead sponsor.

NCT NCT01915108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01915108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal During Emergence From Sevoflurane-remifentanil Anesthesia
Lead sponsor
Sangjin Park
Phase
Not applicable
Overall status
Completed
Start date
July 31, 2012
Completion date
June 30, 2013
Enrollment
128 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory complication